Edgewise Therapeutics (EWTX) Proxy filing summary

Executive summary

• Focuses on developing innovative treatments for severe muscle diseases, leveraging a proprietary muscle-focused drug discovery platform and engaging closely with patient communities.

• Strategic priorities include advancing clinical programs for muscular dystrophies and hypertrophic cardiomyopathy, expanding the pipeline, and evaluating strategic collaborations.

• 2025 business highlights include positive clinical trial results for sevasemten and EDG-7500, and initiation of a new Phase 1 study for EDG-15400.

Voting matters and shareholder proposals

• Shareholders will vote on electing three directors (Laura Brege, Badreddin Edris, Ph.D., Jonathan Root, M.D.) to serve until 2029.

• Proposal to ratify KPMG LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation (Say-on-Pay) is included.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board consists of nine directors, with a majority deemed independent under Nasdaq rules.

• Board leadership is separated between Chairperson and CEO roles.

• Annual board and committee self-assessments, executive sessions of independent directors, and robust stockholder engagement are in place.

• Committees include Audit, Compensation, and Nominating & Corporate Governance, each with defined responsibilities and independent membership.

• Director compensation policy includes cash retainers and equity awards, with recent increases in compensation limits and retainer amounts.